Michelle Ann Lally

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7523768/publications.pdf

Version: 2024-02-01

			236925	1	89892
58		2,621	25		50
papers		citations	h-index		g-index
59		59	59		3871
all docs	•	docs citations	times ranked		citing authors

#	Article	IF	CITATIONS
1	Analysis of 13 cell types reveals evidence for the expression of numerous novel primate- and tissue-specific microRNAs. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1106-15.	7.1	376
2	An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 21-29.	2.1	235
3	Safety and Immunogenicity of a Replicationâ€Incompetent Adenovirus Type 5 HIVâ€1 Clade B <i>gag/pol/nef</i> Vaccine in Healthy Adults. Clinical Infectious Diseases, 2008, 46, 1769-1781.	5 . 8	215
4	Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States. JAMA Pediatrics, 2017, 171, 1063.	6.2	178
5	The Acceptability and Feasibility of an HIV Preexposure Prophylaxis (PrEP) Trial With Young Men Who Have Sex With Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 62, 447-456.	2.1	159
6	A Phase IIA Randomized Clinical Trial of a Multiclade HIV-1 DNA Prime Followed by a Multiclade rAd5 HIV-1 Vaccine Boost in Healthy Adults (HVTN204). PLoS ONE, 2011, 6, e21225.	2.5	131
7	Laboratory testing for infection with the human immunodeficiency virus: established and novel approaches. American Journal of Medicine, 2000, 109, 568-576.	1.5	109
8	HIV testing and linkage to services for youth. Journal of the International AIDS Society, 2015, 18, 19433.	3.0	83
9	A Trimeric, V2-Deleted HIV-1 Envelope Glycoprotein Vaccine Elicits Potent Neutralizing Antibodies but Limited Breadth of Neutralization in Human Volunteers. Journal of Infectious Diseases, 2011, 203, 1165-1173.	4.0	71
10	Safety and Immunogenicity of Adenovirus-Vectored Near-Consensus HIV Type 1 Clade B <i>gag</i> Vaccines in Healthy Adults. AIDS Research and Human Retroviruses, 2009, 25, 103-114.	1.1	63
11	Keeping the Faith: African American Faith Leaders' Perspectives and Recommendations for Reducing Racial Disparities in HIV/AIDS Infection. PLoS ONE, 2012, 7, e36172.	2.5	63
12	Feasibility and Acceptability of Rapid HIV Testing in Jail. AIDS Patient Care and STDs, 2007, 21, 41-47.	2. 5	55
13	Metformin is Associated with Decreased 30-Day Mortality Among Nursing Home Residents Infected with SARS-CoV2. Journal of the American Medical Directors Association, 2021, 22, 193-198.	2.5	54
14	A review of the case for hepatitis B vaccination of high-risk adults. American Journal of Medicine, 2003, 114, 316-318.	1.5	53
15	HIV Care Providers' Intentions to Prescribe and Actual Prescription of Pre-Exposure Prophylaxis to At-Risk Adolescents and Adults. AIDS Patient Care and STDs, 2017, 31, 504-516.	2.5	52
16	Clinician Attitudes Toward CDC Interim Pre-Exposure Prophylaxis (PrEP) Guidance and Operationalizing PrEP for Adolescents. AIDS Patient Care and STDs, 2015, 29, 193-203.	2.5	47
17	A Mobile Gaming Intervention to Increase Adherence to Antiretroviral Treatment for Youth Living With HIV: Development Guided by the Information, Motivation, and Behavioral Skills Model. JMIR MHealth and UHealth, 2018, 6, e96.	3.7	47
18	Engineering immunogenic consensus T helper epitopes for a cross-clade HIV vaccine. Methods, 2004, 34, 476-487.	3.8	42

#	Article	IF	Citations
19	A Qualitative Study Among Injection Drug Using Women in Rhode Island: Attitudes Toward Testing, Treatment, and Vaccination for Hepatitis and HIV. AIDS Patient Care and STDs, 2008, 22, 53-64.	2.5	42
20	Quantitative proteomic analysis of exosomes from <scp>HIV</scp> â€1â€infected lymphocytic cells. Proteomics, 2012, 12, 2203-2211.	2.2	42
21	Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth. AIDS Patient Care and STDs, 2016, 30, 339-348.	2.5	41
22	Comprehensive Medical Care among HIV-Positive Incarcerated Women: The Rhode Island Experience. Journal of Women's Health and Gender-Based Medicine, 2000, 9, 51-56.	1.5	36
23	Predictors of Over-Reporting HIV Pre-exposure Prophylaxis (PrEP) Adherence Among Young Men Who Have Sex With Men (YMSM) in Self-Reported Versus Biomarker Data. AIDS and Behavior, 2018, 22, 1174-1183.	2.7	36
24	Profiles of Medicinal Cannabis Patients Attending Compassion Centers in Rhode Island. Journal of Psychoactive Drugs, 2015, 47, 18-23.	1.7	32
25	<i>Legionella bozemanii</i> Pneumonia in Three Patients with AIDS. Clinical Infectious Diseases, 1998, 27, 97-99.	5. 8	29
26	Youth-Specific Considerations in the Development of Preexposure Prophylaxis, Microbicide, and Vaccine Research Trials. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, S31-S42.	2.1	25
27	Preventive misconception and adolescents' knowledge about HIV vaccine trials. Journal of Medical Ethics, 2013, 39, 765-771.	1.8	24
28	HIV Seroconversion without Infection after Receipt of Adenovirusâ€Vectored HIV Type 1 Vaccine. Clinical Infectious Diseases, 2008, 47, 1593-1599.	5 . 8	21
29	Acceptability of Sexually Transmitted Infection Screening Among Women in Short-Term Substance Abuse Treatment. Sexually Transmitted Diseases, 2002, 29, 752-755.	1.7	19
30	OPRM1 and Diagnosis-Related Posttraumatic Stress Disorder in Binge-Drinking Patients Living with HIV. AIDS and Behavior, 2012, 16, 2171-2180.	2.7	19
31	Evaluation of an Intervention Among Adolescents to Reduce Preventive Misconception in HIV Vaccine Clinical Trials. Journal of Adolescent Health, 2014, 55, 254-259.	2.5	19
32	Integrating Behavioral HIV Interventions Into Biomedical Prevention Trials With Youth: Lessons From Chicago's Project PrEPare. Journal of HIV/AIDS and Social Services, 2013, 12, 333-348.	0.7	18
33	Adolescent decision making about participation in a hypothetical HIV vaccine trial. Vaccine, 2015, 33, 1331-1337.	3.8	18
34	HPV Vaccination Practices Among Juvenile Justice Facilities in the United States. Journal of Adolescent Health, 2010, 46, 495-498.	2.5	17
35	Risk Factors for Syphilis among Incarcerated Women in Rhode Island. AIDS Patient Care and STDs, 2001, 15, 581-585.	2.5	15
36	Hypercalcemia in an AIDS patient treated with growth hormone. Aids, 1997, 11, 1353-1356.	2.2	12

#	Article	lF	Citations
37	HIV TESTING IN THE SETTING OF INPATIENT ACUTE SUBSTANCE ABUSE TREATMENT. American Journal of Drug and Alcohol Abuse, 2001, 27, 491-499.	2.1	11
38	A Model to Provide Comprehensive Testing for HIV, Viral Hepatitis, and Sexually Transmitted Infections at a Short-Term Drug Treatment Center. AIDS Patient Care and STDs, 2005, 19, 298-305.	2.5	11
39	Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants. Vaccine Journal, 2014, 21, 1589-1599.	3.1	10
40	Bundling Human Papillomavirus Vaccination and Rapid Human Immunodeficiency Virus Testing for Young Gay and Bisexual Men. LGBT Health, 2014, 1, 233-237.	3.4	10
41	Routine HIV Testing Among Inpatients. Archives of Internal Medicine, 2002, 162, 2252-2253.	3.8	10
42	HeartÂFailure Outcomes and Associated Factors Among Veterans With Human Immunodeficiency Virus Infection. JACC: Heart Failure, 2020, 8, 501-511.	4.1	9
43	Vaccination in Juvenile Correctional Facilities: State Practices, Hepatitis B, and the Impact on Anticipated Sexually Transmitted Infection Vaccines. Public Health Reports, 2007, 122, 44-48.	2.5	8
44	Correlates of willingness to participate in microbicide research among African Americans. Journal of Health Psychology, 2013, 18, 65-74.	2.3	8
45	Impact of Early Antiretroviral Therapy on Detection of Cell-Associated HIV-1 Nucleic Acid in Blood by the Roche Cobas TaqMan Test. Journal of Clinical Microbiology, 2019, 57, .	3.9	8
46	Willingness to receive an HIV vaccine among incarcerated persons. Preventive Medicine, 2006, 43, 402-405.	3.4	7
47	State-civil society partnerships for HIV/AIDS treatment and prevention in Ghana: exploring factors associated with successes and challenges. BMC Health Services Research, 2016, 16, 332.	2.2	6
48	Stem-loop binding protein is a multifaceted cellular regulator of HIV-1 replication. Journal of Clinical Investigation, 2016, 126, 3117-3129.	8.2	5
49	Age at Diagnosis of Heart Failure in United States Veterans With and Without HIV Infection. Journal of the American Heart Association, 2021, 10, e018983.	3.7	4
50	HIV Testing Among Young Adults and Older Adolescents in the Setting of Acute Substance Abuse Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 135-142.	2.1	3
51	Routine, Not Riskâ€Based, Human Immunodeficiency Virus Testing Is the Way to Go. Journal of Infectious Diseases, 2003, 187, 1024-1024.	4.0	3
52	Where to begin human papillomavirus vaccination?. Lancet Infectious Diseases, The, 2006, 6, 389-390.	9.1	3
53	Web-based, mobile-device friendly, self-report survey system incorporating avatars and gaming console techniques. Online Journal of Public Health Informatics, 2014, 6, e191.	0.7	3
54	HPV Vaccination an Opportune Time for HIV Testing. Journal of Adolescent Health, 2007, 40, 384.	2.5	2

#	Article	IF	CITATIONS
55	HIV Risk Behaviors in Adolescent and Young Adult Substance Users Undergoing Treatment. Journal of HIV/AIDS Prevention and Education for Adolescents and Children, 2002, 4, 43-54.	0.1	1
56	Variation in statin prescription among veterans with HIV and known atherosclerotic cardiovascular disease. American Heart Journal, 2022, 249, 12-22.	2.7	1
57	Avatar Web-Based Self-Report Survey System Technology for Public Health Research: Technical Outcome Results and Lessons Learned. Online Journal of Public Health Informatics, 2016, 8, e189.	0.7	0
58	HIV vaccine update: recent developments and current trials. Medicine and Health, Rhode Island, 2007, 90, 318-20.	0.1	0